VEA
ASND icon

Virtus ETF Advisers’s Ascendis Pharma A/S ASND Stock Holding History

Virtus ETF Advisers’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,676
Closed -$368K – 454
2024
Q4 		$368K Buy
2,676
+100
+4% +$13.1K 0.15% 193
2024
Q3 		$385K Hold
2,576
– – 0.18% 207
2024
Q2 		$351K Sell
2,576
-596
-19% -$81.1K 0.17% 197
2024
Q1 		$480K Buy
3,172
+456
+17% +$65.1K 0.25% 180
2023
Q4 		$342K Sell
2,716
-652
-19% -$65K 0.22% 194
2023
Q3 		$315K Sell
3,368
-434
-11% -$40.6K 0.19% 197
2023
Q2 		$339K Buy
3,802
+1,266
+50% +$110K 0.2% 169
2023
Q1 		$272K Buy
2,536
+45
+2% +$5.15K 0.15% 264
2022
Q4 		$304K Sell
2,491
-409
-14% -$47.5K 0.16% 258
2022
Q3 		$299K Buy
2,900
+44
+2% +$4.17K 0.12% 276
2022
Q2 		$265K Buy
2,856
+134
+5% +$12.6K 0.1% 286
2022
Q1 		$319K Hold
2,722
– – 0.14% 171
2021
Q4 		$366K Buy
2,722
+1,141
+72% +$170K 0.14% 178
2021
Q3 		$252K Sell
1,581
-83
-5% -$11.4K 0.11% 218
2021
Q2 		$219K Buy
1,664
+23
+1% +$3.06K 0.09% 278
2021
Q1 		$211K Buy
1,641
+27
+2% +$4.1K 0.09% 319
2020
Q4 		$269K Sell
1,614
-601
-27% -$99.4K 0.11% 279
2020
Q3 		$342K Sell
2,215
-296
-12% -$42.5K 0.18% 190
2020
Q2 		$371K Sell
2,511
-606
-19% -$83.2K 0.18% 232
2020
Q1 		$351K Sell
3,117
-452
-13% -$58.7K 0.14% 207
2019
Q4 		$497K Buy
3,569
+1,471
+70% +$163K 0.08% 203
2019
Q3 		$202K Sell
2,098
-116
-5% -$12.9K 0.04% 251
2019
Q2 		$255K Sell
2,214
-2,036
-48% -$244K 0.05% 270
2019
Q1 		$500K Sell
4,250
-539
-11% -$47.2K 1.06% 29
2018
Q4 		$300K Buy
+4,789
New +$301K 0.05% 110

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Virtus ETF Advisers's ASND Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Ascendis Pharma A/S (ASND) in Q1 2025, closing a stake of 2,676 shares — an estimated $368K sold.

Virtus ETF Advisers first reported a position in ASND in Q4 2018 and held it in 25 quarters. The position peaked at $500K in Q1 2019. 244 funds tracked by Wall St. Rank hold ASND as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Ascendis Pharma A/S position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 2,676 Ascendis Pharma A/S shares in Q1 2025, an estimated $368K.
  • Virtus ETF Advisers first reported a position in Ascendis Pharma A/S in Q4 2018 and held it in 25 quarters.
  • Virtus ETF Advisers's Ascendis Pharma A/S position peaked at $500K in Q1 2019.
  • 244 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.